Objective: The aim of this study was to examine the effect of hormone therapy and calcitriol on depression in older postmenopausal women and to determine whether the response was associated with polymorphisms of estrogen receptor > and vitamin D receptor.
L ate-life depression is a common cause of disability in people older than 65 years because of biological, psychological, and social risk factors that come with age. The prevalence is approximately between 8% and 39%, and it varied in different settings. 1, 2 This has become a public health burden because it leads to decreased quality of life and increased hospitalization, 3 and it is often underdiagnosed and undertreated 4 in primary care settings because many older people may not present with typical symptoms of depression such as sadness 5 or they may consider depressed mood as a normal part of aging even though it is not. 6 Older women are known to have a higher risk of developing depression compared with men. 7 This could be partly caused by loss of estrogen with menopause because estrogen is known to have neuroprotective effects on the brain, 8 but when progestins are added to estrogens, this effect may diminish. 9 Hormone therapy (HT) may improve the symptoms of depression in depressed people 10 or decrease the risk of developing depressive symptoms in older women, 11 but this is unclear because in some studies, HT does not stop the development of depressive symptoms in older postmenopausal women. 12<14 The exact role of estrogen still needs to be defined. The genomic actions of estrogen are exerted through two kinds of receptorsVestrogen receptor > (ER->) and A (ER-A). Two commonly known single nucleotide polymorphisms (SNPs) of the ER-> receptor are PvuII (rs2234693) and XbaI (rs9340799). Polymorphisms of the ER-> have been associated with psychiatric disorders like Alzheimer disease, 15 and one study has shown an association between ER-> genotype polymorphisms and depression in women, 16 but their exact role in depression has not been clearly defined.
Older people are also at higher risk of developing vitamin D deficiency because of decreased dietary intake, less sun exposure, restricted outdoor activity, and a decreased capacity to produce enough calcitriol because of an age-related decline in hydroxylation by the kidneys. Besides playing a role in calcium homeostasis, vitamin D also has the potential for a neuroactive effect on brain function 17 through the vitamin D receptor (VDR). Low vitamin D levels may be associated with depression in older people, 18, 19 and taking supplements may improve the symptoms of depression. 20 Despite these findings, the associations are not conclusive because some studies did not find any association, 21, 22 and most of the studies that found an association between vitamin D and depression are crosssectional, observational, or small sample studies with methodological problems. Although VDR genotype polymorphisms were shown to be associated with bone mineral density and risk of fractures, 23 their role in the pathology of depression has not been clearly established.
There are a few prospective studies that have evaluated the relationship between either HT and depression or vitamin D and depression. However, to our knowledge, there were no studies that evaluated the effect of HT given with vitamin D along with their individual effects on depression in older postmenopausal women. In addition, few studies examined the relation between ER-> gene polymorphisms and depression, 24, 25 and one study examined the association of VDR gene polymorphisms with depression. 26 In this 3-year doubleblind placebo-controlled intervention study, the primary outcome was the effect of HT and calcitriol either individually or in combination on age-related bone loss in older postmenopausal women. However, we also collected Geriatric Depression Scale (GDS) scores at baseline and at the end of 36 months (final visit), and the purpose of this article was to provide a secondary analysis of the longitudinal effect of hormone therapy and vitamin D on depression along with the role of ER->, VDR genotype polymorphisms, and serum levels of estradiol, sex hormoneYbinding globulin (SHBG), and testosterone.
METHODS
The participants in this study (Sites Testing Osteoporosis Prevention or Intervention Treatment) are 489 communitydwelling older postmenopausal women aged between 65 and 77 years who were tested for the effect of HT and calcitriol either individually or in combination on age-related bone loss. The participants were randomly assigned to one of the four groups through a computer-generated randomization listV conjugated equine estrogens 0.625 mg/daily (estrogen therapy [ET]) in hysterectomized women (or combined with medroxyprogesterone acetate 2.5 mg/daily [estrogen + progestogen therapy] in women with intact uterus); calcitriol 0.25 g BID; combination group (HT + calcitriol), and matching placebos. All women were given two pills (placebo and intervention pill), and placebo pills were made to appear identical to the treatment pills. Compliers in this study were defined as those who were 80% or more compliant in taking the study medication. Compliance was estimated by pill counts. Compliance at 36 months was 92% in the group taking conjugated estrogens, 94% in the group taking medroxyprogesterone acetate, 93% in the group taking calcitriol, and 92% in the group taking placebos.
Women who had chronic illness, primary hyperparathyroidism, or active renal stone disease, and who were taking certain medications, such as bisphosphonates, anticonvulsants, estrogen, fluoride, or thiazide diuretics in the last 6 months were excluded from the study. The protocol was reviewed and approved by an institutional review board, and all participants were randomized only after signing an informed consent form. The National Institutes of Health established a Data Safety and Monitoring Board to monitor the study. Full details of the methodology can be obtained from the previously published analysis. 27 GDS score measurement GDS-Long Form 30 was used to collect data on depressive symptoms, consisting of 30 depression-related self-rating questions with simple Byes[ or Bno[ options and a score ranging from 0 to 30. This scale was exclusively developed for screening and rating the severity of depression in older people and has shown very good criterion validity. When a cutoff score of 11 is used, it has a sensitivity of 84% and specificity is 95%. 28 We used the same cutoff value to differentiate between nondepressed and depressed (0-10, nondepressed; 11-30, depressed). The GDS scores were collected at baseline and at the end of the study. At baseline, we also collected information about other associated variables such as level of education, previous history of depression, history of hypothyroidism, living status, smoking habits, and alcohol consumption.
Genotyping
Genotyping was performed on DNA extracted from the participants' white blood cells using Puregene kit (Gentra Systems) for ER-> SNPs and standard phenol/chloroform extraction procedure for VDR SNPs (BsmI-rs1544410 and TaqI-rs1544410). Genotype coding for ER-> restriction sites was Pp for PvuII and Xx for XbaI. For VDR SNPs, Bb denotes BsmI and Tt denotes TaqI. Uppercase and lowercase letters denoted the presence and absence of restriction sites, respectively. Polymerase chain reaction was used to extract DNA, and the products were digested using appropriate restriction endonucleases. The fragments were processed using gel electrophoresis, stained with ethidium bromide for clear visualization under ultraviolet light, and photographed.
Biochemical measurements
Serum 25-hydroxyvitamin D (25(OH)D) was assayed with a competitive protein-binding assay. Serum total estradiol, SHBG, and serum total testosterone were measured in fasting baseline serum samples using radioimmunoassay kits (Diagnostic Systems Laboratories, Webster, TX). The intra-assay coefficient of variation for the assays was as follows: serum 25(OH)D, 5.1%; estradiol, 4.1%; SHBG, 8.2%; and testosterone, 7.4%.
Statistical methods and analyses
All analyses were performed using SPSS version 19 (IBM SPSS Inc.). Baseline characteristics were compared among the four treatment groups using one-way analysis of variance (ANOVA) for continuous variables and a W 2 test for categorical variables.
For the baseline cross-sectional analysis, we categorized 25(OH)D level into vitamin D insufficient or sufficient based on a cutoff of 20 ng/mL and used a W 2 test to find correlation with depression (yes/no). To compare genotype polymorphisms among depressed and nondepressed people, we used W 2 tests and to compare genotype polymorphisms and response to treatment (defined as difference between final GDS and baseline GDS score), we used linear regression. We used one-way ANOVA to find associations between baseline depression and serum total estradiol, SHBG, and total testosterone.
For the longitudinal analyses, we used binary logistic regression analysis to determine the effect of HT and calcitriol on depression. The final GDS score was categorized into depressed or nondepressed and was used as the dependant variable and the treatment group (placebo as reference) as the categorical variable in binary logistic regression. We also did a subgroup analysis on depressed people at baseline using one-way ANOVA to find the effect of treatment. The CIs estimated for odds ratios of depression were calculated with 95% probability. The significance level was set to 0.05 for all analyses in our study. We performed the modified intent-totreat analyses on 412 participants who came in for both the baseline and final visit. In addition, we performed longitudinal analysis on compliers (n = 337). One-way analysis of variance was used for comparing continuous variables and W 2 test for categorical variables.
d RESULTS A total of 489 participants were enrolled in this study. One participant was excluded because of new-onset Paget disease. All participants completed the GDS questionnaire at baseline (n = 488). At the end of the study, 412 participants (85%) completed the GDS questionnaire and 76 women (15%) did not complete it (nonresponse) and 337 finished on active drug (compliers). Our study population was successfully randomized, and the groups did not differ significantly from each other. Baseline characteristics are summarized in Table 1 .
The mean age was 71.4 (SD, 3.6) years. Nineteen (4%) women were taking antidepressants at baseline, but we found that 57 (12%) women had depression based on baseline GDS scores. There were 89 (18%) women who were hypothyroid and 189 (39%) were living alone. There were 199 (41%) hysterectomized women and 289 (59%) nonhysterectomized women. There were 57 (12%) participants who were minimally educated.
The mean GDS score at baseline was 4.8 (SD, 4.6), and at 36 months, it was 4.2 (SD, 4.2). Mean serum 25(OH)D was 31.3 (SD, 10.5) ng/mL. Mean serum total estrogen was 11.95 (SD, 5.07) pg/mL, mean SHBG was 147.47 (SD, 67.7) nmol/L, and mean total testosterone was 0.23 (SD, 0.11) nmol/L. There were 57 women with depression at baseline, 17 women receiving placebo, 10 women receiving HT with calcitriol, 18 women receiving HT only, and 12 women receiving calcitriol only. At the final visit, the number of women with depression decreased in all the groups regardless of intervention given: placebo, 11 women; HT with calcitriol, 8 women; HT, 14 women; and calcitriol, 9 women.
The distribution of ER-> (XbaI, PvuII) and VDR (BsmI, TaqI) genotypes in our study population followed the HardyWeinberg equilibrium.
Intent-to-treat cross-sectional analysis at baseline Serum 25(OH)D levels and depression
At baseline, W 2 analysis between serum 25(OH)D and depression showed no significant correlation (W 2 = 0.944, P = 0.331).
ER-> polymorphisms and depression
The W 2 analysis showed no significant association between depression and ER-> polymorphisms XbaI and PvuII (W 2 = 0.894, P = 0.640 and W 2 = 0.215, P = 0.898, respectively).
VDR polymorphisms and depression
At baseline, depression did not show any association with VDR polymorphisms BsmI and TaqI (W 2 = 0.771, P = 0.680 and W 2 = 0.901, P = 0.637, respectively).
Total estradiol, SHBG, and total testosterone and depression Serum total estradiol, SHBG, and total testosterone levels did not show any significant difference between depressed and nondepressed people at baseline (F = 0.014, P = 0.904; F = 0.014, P = 0.953; and F = 1.561, P = 0.212, respectively).
Intent-to-treat longitudinal analysis
In the modified intent-to-treat analysis (n = 412), we used binary logistic regression to find the effect of intervention on depression, and there was no effect of HT (OR, 1.65; 95% CI, 0.66-4.12; P = 0.277), calcitriol (OR, 1.15; 95% CI, 0.43-3.11; P = 0.772) or HT + calcitriol (OR, 1.01; 95% CI, 0.36-2.80; P = 0.979) on depression ( Table 2) .
In subgroup analysis using one-way ANOVA, all the participants who were depressed at baseline showed a significant improvement in depression (final GDS j baseline GDS) when compared with nondepressed people (F = 68.82; P G 0.0001). This improvement was seen in placebo and in all treatment groups (Fig. 1) . The response to treatment (defined as difference in final and baseline GDS scores) was not associated with ER-> and VDR polymorphisms (A = 0.093; CI, j0.337 to 1.350, P = 0.239 for XbaI; A = j0.064; CI, j1.171 to 0.491, P = 0.421 
FIG. 1.
Comparison of mean change in GDS scores in depressed and nondepressed people. Error bars represent 95% CI. HT is either with conjugated equine estrogens 0.625 mg/daily in hysterectomized women or combined with medroxyprogesterone acetate 2.5 mg/daily in women with intact uterus. Calcitriol dose is 0.25 g twice daily. y axis represents mean of difference between final GDS and baseline GDS. GDS, Geriatric Depression Scale; HT, hormone therapy.
for PvuII; A = 0.044; CI, j2.546 to 3.030, P = 0.865 for BsmI; and A = j0.015, CI, j2.900 to 2.738, P = 0.955 for TaqI).
Complier longitudinal analysis
Among compliers (n = 337), the results remain unchanged, and there was no effect of HT (OR, 2.22; 95% CI, 0.77-6.42; P = 0.140), calcitriol (OR, 1.77; 95% CI, 0.59-5.30; P = 0.305) or HT + calcitriol (OR, 1.19; 95% CI, 0.34-4.18; P = 0.776; see Table 2 ).
DISCUSSION
The purpose of this secondary analysis was to see whether HT and calcitriol, either combined or individually, had an effect on depression in older postmenopausal women and to see whether there was any relationship between depression and polymorphisms of ER-> and VDR. We believe that this is the first study to compare the combined and individual effects of HT/ET and calcitriol on depression longitudinally. The evaluation of association between ER->, VDR genotype polymorphisms, estradiol, SHBG, testosterone, and depression provides an insight for future researchers.
It has been shown in several studies that estrogen has either a weak or no association with depression. Two large trials, the Women's Health Initiative (WHI) and The Women's International Study of Long-Duration Oestrogen After Menopause (WISDOM), failed to demonstrate an improving effect of HT on depression. The WHI trial was unable to demonstrate a benefit of estrogen on depressive symptoms and effect. 29 In a recent double-blind placebo-controlled trial involving 3,721 women between 50 and 69 years old, it was shown that combined HT had no effect on depression. 30 In addition, in a study from three French cities (Three-City Study), after evaluation of 4,069 postmenopausal older women by giving HT and following up for 4 years, the authors could not find a protective effect of estrogen against the emergence of depressive symptoms. 31 Our results support these findings because HT showed no influence on depression. In contrast, a meta-analysis of the effect of HT on depressive mood by Zweifel and O'Brien 32 suggested a moderate to large effect of HT on depressed mood. 32 However, estrogen alone (ET) had an effect but not when combined with medroxyprogesterone acetate (HT). In our analysis, women in the estrogen-only group were not influenced by treatment.
Depression is thought to be caused by an alteration in the serotonergic system, although other neurotransmitters are also involved. Estrogen is known to have a modulating effect on all of these neurotransmitter pathways, especially the serotonergic pathway. 33 In one study, conjugated equine estrogens therapy improved mood in depressed postmenopausal women. 34 There are some data suggesting that progestins can antagonize the neuroprotective effects of estrogen. 9 However, we saw no significant difference in the response to estrogen alone or combined with progestin.
The effect of vitamin D on depression in the older population has not been studied extensively. Although few prospective studies demonstrated a relationship between vitamin D and depression, there exists a controversy. In a cohort study of 1,155 participants older than 65 years, low levels of serum 25(OH)D (G50 nmol/L) were associated with depressive symptoms, and the association was higher in women than in men. 35 However, in our study, the baseline analysis did not show a relationship between baseline serum 25(OH)D insufficiency (G20 ng/ml) and depression. At the end of our study, there was no effect of vitamin D supplementation on depression.
Recently, in a large randomized, placebo-controlled trial conducted by Sanders et al 22 in Australia involving 2,317 older women, the annual high dose of vitamin D 3 (500,000 IU) with 3-year follow-up failed to prevent depressive symptoms. 22 In a cross-sectional study by Jorde et al 20 involving 441 obese men and women, it was shown that participants with serum 25(OH)D levels more than 40 nmol/L were associated with low depression scores on the Beck Depression Inventory, but this study was unadjusted for the common confounders. 20 In another study on a small group of 21 older participants with secondary hyperparathyroidism not caused by renal failure, they found that low serum 25(OH)D (50 nmol/L) was associated with a lower depression score. 36 Recently, evidence from a WHI analysis of the relationship between vitamin D intake from foods and supplements and depressive symptoms supports our finding that the supplementation of vitamin D was not associated with depressive symptoms. 37 We could not find any significant relationship between serum 25(OH)D levels and depression.
Although several other studies demonstrated an association between low levels of serum 25(OH)D and major depressive disorder 38 and also between vitamin deficiency and low mood, 19 long-term treatment in this study did not show an effect of calcitriol in postmenopausal women. No previous study has evaluated the combined effect of HT with calcitriol, but no significant improvement in depression was observed in this study.
Genotypes can affect the response to treatment as found in the studies with regard to changes in lipids and bone density. 23, 39 In one study by Malacara et al 24 in 177 postmenopausal women, the authors did not find a significant association between ER-> genotypes (PvuII and XbaI) and depression. 24 Another study reported increased risk of anxiety with ER-> polymorphisms but not depressive symptoms. 25 However in a case-control study by Kim et al, they found a strong association between ER polymorphism and depression in postmenopausal women. 40 Similarly, in the Three-City Study, Ryan et al 16 found that two polymorphisms of ER-> and one polymorphism of ER-A were associated with depression in women. 16 In our study, we did not find an association between either ER-> or VDR genotype polymorphisms and depression.
Vitamin D responsive elements are present in the promoter regions of serotonin receptors and tryptophan hydroxylase receptors, both of which are known to be associated with depression. 41 In one study, it was shown that VDR polymorphisms influence the susceptibility to depression in old age, between VDR polymorphisms and depression or the response to treatment. We recommend larger studies to confirm these genotype findings.
The strengths of this study are the large postmenopausal population with 3-year follow-up, excellent validity of the GDS-Long Form 30 scale, which is a powerful screening tool covering a wide range of depressive symptoms, and baseline adjustment to the known potential confounders. The unique strength of this study was the combination effect of HT and calcitriol on depression. However, all data collected on depression were self-reported instead of clinically diagnosed. Recall bias may have had an effect because of the age of the population. We had no data on socioeconomic status, which is one of the known confounders. The finding that all the women showed improvement irrespective of intervention given might be caused by the regression to mean (floor effect) because they have more chance for improvement compared with nondepressed people. In retrospect, our study did not have sufficient numbers of depressed people with blood levels representative of moderate to severe vitamin D deficiency. Moreover, larger studies will be required to confirm genotype association with depression because of the low number of depressed people in our study.
CONCLUSIONS
In summary, neither HT nor calcitriol either individually, or in combination, showed a statistically significant effect on depression in older postmenopausal women. There was no evidence that ER-> and VDR polymorphisms were associated with depression or the response to treatment in older postmenopausal women.
